This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Purdue Pharma Increases Adoption Of Medidata Clinical Cloud To Strengthen R&D Operations

Medidata Solutions (NASDAQ: MDSO) signed Purdue Pharma L.P. to a multi-year enterprise agreement that significantly broadens its already wide use of Medidata’s cloud-based solutions, to further improve clinical trial operational efficiencies, resource savings and decision making. Purdue is also renewing the Medidata applications it currently uses across its portfolio of innovative treatments for pain, sleep and gastrointestinal disorders.

Relying on a range of Medidata products for all major studies since 2010, including study and protocol design tool Medidata Designer ® and electronic data capture and management system Medidata Rave ®, Purdue recently adopted Medidata’s clinical trial management system (CTMS) and is now adding clinical business analytics with Medidata Insights™, including its innovative site quality management module, as well as support for risk-based monitoring with Rave Targeted SDV and additional modules of the site budgeting and financial management tool Medidata Grants Manager ®.

For the past three years, Purdue’s management has witnessed significant productivity improvements in its clinical trial operations with Medidata’s cloud-based solutions. Before expanding its use of the Medidata platform, Purdue conducted a complete ROI analysis to secure buy-in from executive management on the implementation.
  • “After seeing the results we were able to achieve with Medidata’s Clinical Cloud, we have enthusiastically embraced a number of new capabilities,” said Charles Willmer, senior director of clinical systems, Purdue. “Expanding our use of Medidata’s platform will enable us to reduce cost, complexity and time in site negotiation and monitoring, track CRO activities more efficiently, and improve visibility into study performance.”

Using Medidata Designer, Purdue has streamlined the design process and increased downstream visibility into the impacts of design decisions, leading to improvements in quality and timelines. Purdue’s use of Medidata Rave for data management and capture across its global trials is driving fast trial start-up times: study build timelines have decreased to less than eight weeks. The company is also leveraging Rave’s standards-based infrastructure to easily import data from other clinical technologies for additional study efficiencies.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs